The purpose of this study was to evaluate the pharmacological and toxicological effects of exogenous GH administration in normal adult dogs. Because porcine GH (pGH) is structurally identical to canine GH, pGH was selected for a 14-wk study in dogs. Thirtytwo dogs (<2 yr) were randomized to 4 groups (4 dogslsexlgroup); 1 group was treated with the vehicle and 3 groups received pGH at 0.025. 0.1, or 1.0 IU/kg/day subcutaneously. Daily clinical signs and weekly body weights were recorded. Hematology, serum biochemistry, urinalyses, electrocardiograms, and ophthalmoscopic examinations were done. Serum GH, insulin-like growth factor-1 (IGF-I), insulin, thyroxine (T4), triiodothyronine (T3). and cortisol levels werc determined. Necropsies were performed, organs weighed, and tissues were fixed and processed for light microscopic examination. Porcine GH caused increased body weight gain (p 5 0.05) through the mid dose; the mean weight gains at study termination in mid-and high-dose groups were 2.8 kg and 4.7 kg.
INTRODUCTION
Growth hormone (GH) plays an important role in metabolism in addition to its well-known effect on body growth. In children with GH deficiency, beneficial effects of chronic GH administration have been well established. Exogenous GH administration results in high circulating levels of GH in contrast to the pulsatile pattern release of endogenous GH; this could potentially lead to exaggerated indirect (anabolic) and direct (catabolic) GH effects. Therefore, newer approaches are being considered to facilitate release of endogenous GH using GH secretagogues to avoid exposure to high bolus doses of exogenous GH. GH secretagogues are a class of peptidyl or nonpeptidyl compounds that are being developed as oral compounds for the treatment of conditions in man that may benefit from augmentation of the GH axis (2, 3, 13, 14, 24).
In order to evaluate adequately the safety of a GH secretagogue, it is important to define the pharmacological effects of increased circulating GH levels as well as to evaluate the potential direct toxicity of the GH secretagogue itself. Based on available data of GH effects in dogs (7) . it appears that the dog is an appropriate model in which to evaluate the pharmacological and toxicological effects of GH secretagogues. It is well known that chronic elevation of GH (spontaneous or experimental) levels leads to an acromegalic-like condition and is diabetogenic in dogs (6, 7, 8, 23, 26) . In most of these studies, increased circulating progesterone (endogenous or exogenous) levels were the underlying cause of GH elevation in dogs. There are no detailed published studies evaluating the direct systemic effects of GH elevation in dogs. The objective of this study was to determine the pharmacological and toxicological effects of chronic porcine GH (pGH) administration in dogs. It has been shown that canine GH and pGH have identical protein structures (1); therefore, pGH was selected for the study in dogs.
MATERIALS AND METHODS
Aniinals and Animal Husbandry. Sixteen male and 16 female beagle dogs, 54-69 wk old (6.9-15.7 kg at study start), from Hazleton Research Products, Inc. (Kalamazoo, MI) and Marshall Farms (North Rose, NY) were used. Dogs were assigned to dosage groups with dogs from both vendors represented within a dosage group and litter mates prohibited. Dogs were selected for study based on acceptable pretest hematologic, serum biochemical and urinalysis values, ophthalmoscopic and electrocardiographic evaluations, and general physical appearance.
Dogs were housed in individual stainless steel pens, in environmentally controlled rooms with a 12-hr light cycle, and were individually identified with tattoos. Approximately 350 g of Purina Certified Canine Chow biscuits was provided once daily until week 10 of the study, when the ration was increased to 550 g daily for all dogs; drinking water was available ad libitwn. Food was withdrawn overnight prior to scheduled venipunctures for hematology and serum biochemical sample collections (except serum hormone samples) and necropsy. Dogs were weighed pretest and once weekly throughout the study; food consumption generally was measured 4 days per week. All procedures were approved by the Institutional Animal Care and Use Committee at Merck Research Laboratories (West Point, PA).
Conipoiind Adniiitistration. There were 4 dogs/sex/ group. Porcine GH was obtained from Dr. Parlow (Research and Education Institute, Inc., Torrance, CA). Porcine GH was administered subcutaneously daily for 14 wk as a sterile solution of 0.03 M sodium bicarbonate (NaHCO,) in 0.15 M sodium chloride (NaCl), final pH 9.5. The doses of pGH were 0.025 IU/kg/day (0.014 mg/kg/day), 0.1 IU/kg/day (0.056 mg/kg/day), and 1.0 IU/kg/day (0.56 mg/kg/day). The lowest dose (0.025 IU/kg/day) of pGH selected is roughly equivalent to the therapeutic dose of recombinant human GH and the mid and high dose represent multiples of human dose. The subcutaneous injection was rotated among 7 sites on the back of each dog identified by clipping hair. Each site was injected once per week. The control group of dogs received 0.2 mVkg of the vehicle: 0.03 M NaHCO, in 0.15 M NaCl, adjusted to a final pH of 9.5.
Ophthalmoscopic Exainiiintions and Electrocardiograms. Ophthalmoscopic examinations were conducted during the pretest period, and in study weeks 5 and 13, on all dogs on study. Similarly, electrocardiograms were recorded from all dogs during the pretest period and in study weeks 6 and 12, in lateral recumbency.
Hematology, Serion Biochentistry, and Urine Analyses. Hematologic and serum biochemical parameters were determined from samples collected from all animals in the pretest period and in study weeks 3, 7, and 11.
Hematologic examinations were done on blood withdrawn from jugular veins into vacutainers (with EDTA), and the following parameters were determined: erythrocyte count, hemoglobin, hematocrit, mean corpuscular volume, leukocyte count, mean corpuscular hemoglobin, differential leukocyte count, mean corpuscular hemoglobin concentration, prothrombin time, activated partial thromboplastin time, and platelet count. In addition, a 3-ml blood sample (EDTA tube) was collected in study week 12 from all dogs for determination of glycosylated hemoglobin concentration.
Serum biochemical determinations performed were total protein, albumin, glucose, urea nitrogen, creatinine, albumirdglobulin ratio, alkaline phosphatase, cholesterol, triglycerides, sodium, potassium, chloride, phosphorus, calcium, aspartate transaminase, and alanine transaminase. In addition, blood samples from the pretest period and study week 12 were tested for circulating pGH antibodies.
Urine samples were collected from all animals overnight (study weeks 3, 7, 11) and analyzed for protein, bilirubin, glucose, volume, occult blood, pH, specific gravity, ketones, urobilinogen, and microscopic examination of sediment.
Serum Hormone Level Detenniiiations. A 5-ml blood sample was collected immediately prior to dosing (0 hr) and at 0.5, 1, 2, 6, 8, and 24 hr postdose from all dogs during pretest and in study weeks 4, 8, and 12 for the determination of serum GH, insulin-like growth factor-1 (IGF-1), cortisol, insulin, triiodothyronine (T,), and thyroxine (T4) levels. Dogs were not fasted overnight for blood sampling.
These samples were separated into aliquots and frozen. The samples were analyzed for IGF-1 by a specific radioimmunoassay (4). The pGH radioimmunoassay (RIA) kit was purchased from Dr. Parlow. The procedure for RIA has been previously described (17) .
Serum cortisol concentrations were assayed with a kit for human use (Coat-A-Count@ Cortisol from Diagnostic Product Corporation, Los Angeles, CA) with modifications recommended by the manufacturer for its veterinary application. Modifications consisted of doubling of the incubation time and using a modified calibration curve to accommodate the lower values found in dogs. The standards from the kit were diluted with the zero calibrator in order to obtain a standard curve ranging from 0.125 to 12.5 pg/dl (7 standard points). All assays were run in duplicate. Standards and unknown samples (100 pl each) were pipetted into test tubes coated with anticortisol antibodies. One milliliter of '251-cortisol was added to each tube. After a 90-min incubation at 37°C. the liquid was decanted and the activity remaining in the tube was determined using a gamma counter. Unknown values were interpolated from the standard curve. To validate the as-' say, the parallelism of serial dilutions of canine sera to the standard curve was verified. The recovery obtained after adding various amounts of standard cortisol to ca-. nine serum samples was satisfactory. Intra-assay and interassay precision, expressed as coefficient of variation, were determined at 3 different levels and were comprised between 4.2% and 7.5%, and 7.5% and 9.3%. respec stomach, liver, gallbladder, pancreas, pituitary, thyroid, parathyroid, kidneys, ovaries, injection sites, skin, spleen, bone, bone marrow, and peripheral nerve. In addition, the following tissues were also examined from control and high-dose (1 .O IU/kg/day) dogs: salivary gland, small intestine, large intestine, adrenal, urinary bladder. testis, uterus/prostate, skin, mammary gland, lung, heart, lymph node, thymus, skeletal muscle, brain, spinal cord, eye, and optic nerve. In addition to routine skeletal muscle sampling, both cranial tibialis muscles were removed, weighed, and samples fixed for light and/or transmission electron microscopy or frozen for immunohistochemistry. The results of the findings in the skeletal muscle are reported in detail in the accompanying paper (20). A portion of the pituitary was fixed in 4F1G for transmission electron microscopy. The results of the findings in the pituitary are the subject of the accompanying paper (16).
Statistical Analysis. The organ weights were analyzed (males and females separately) for normality using the Wilk-Shapiro W-statistic (22) and for homogeneity of variance using Levene's test (18) . Serum hormone data were summarized by calculating the area under the curve (AUC) for 0-8 hr postdose, using the trapezoidal rule. Missing observations were estimated using least-squares methodology (25). For insulin, the value 2.5 pIU/ml was used for measurements below the 5 pIU/ml lower limit of quantitation, and the value 400 pIU/ml was used for measurements above the 400-pIU/ml upper limit of quantitation. The logarithm of AUC was used in all statistical tests.
The NOSTASOT (no statistical significance of trend) sequential trend test (27) was used to assess a trend in dose of pGH. In this procedure, trend was defined as the progressiveness of response with increasing dose. Analysis of variance was used for organ weights. Separate analyses of covariance, with covariate pretest AUC, were used for each serum hormone variable, drug week, and sex. Due to the large spacing between doses, the trend test was performed only on the ordinal dose scale. The 
RESULTS
For most parameters evaluated, the results were similar in both male and female dogs; therefore, the results were combined for purposes of discussion unless specified.
Physical Signs and Body Weight Changes
The pGH injections were well tolerated by dogs with no physical signs of local imitation or systemic toxicity. In pGH-treated dogs, increased skin thickness as evidenced by heavily folded skin was noted, especially on the head (details discussed later). During the course of the study, there was no evidence of local or generalized edema. All dogs survived to the scheduled necropsy in study week 14. There was a dose-related increase in body weight gain in pGH-treated dogs that was statistically significant (p 5 0.05) through the mid dose (0.1 IU/kg/day) in both sexes. At study termination, the magnitude of mean increases in body weight gains were 0.8, 2.8, and 4:7 kg at 0.025, 0.1, and 1 IU/kg/day dose, respectively, compared to 0.4 kg in controls. As shown in Fig. 1 , the magnitude of mean weight gain expressed as a percent change from pretest weight was approximately 20% and 4096, in mid-and high-dose groups, respectively. The GH-related weight gain was evident within 2-3 wk after initiation of treatment; however, the rate of weight gain began to plateau beginning with week 6 of the study. Therefore, the food ration was increased from 350 g/day to 550 dday beginning week 10 of the study. Associated with an increased food consumption (400-550 dday instead of 350 g), there were further increases in body weight gains in mid-and high-dose dogs. A minimal or no increase in food consumption was evident following increase in food ration to low-dose and control groups in week 10 of the study. The reason for increasing the food ration is discussed under hematologic findings below. There were no drug-related ophthalmologic or electrocardiographic changes in dogs. not considered biologically significant. The anemia was nonregenerative, and the results of the bone marrow (discussed later) evaluation are consistent with the hematological findings.
As shown in Table I , a dose-and time-dependent increase (p I 0.05) in mean platelet count relative to control group was seen in high-dose (1 IU/kg/day) dogs; the mean percent increase over control value was 1096, 3596, 57%, and 72% in study weeks 3, 7, 11, and 14, respectively. In the mid-dose group of dogs, the increase in platelet count was significantly (p 5 0.05) increased only in study week 14. Platelet count in the low-dose group was similar to control group. In addition, the activated partial thromboplastin time (APTT; sec) was decreased in a dose-related manner beginning study week 7 in midand high-dose dogs. The decrease at the lowest dose (0.025 mg/kg/day) was significant (p 5 0.05) in week 11 in males only (Table I ). There were no other pGH-related hematological changes in dogs.
Serum Biocheniical Cliaizges
A spectrum of serum biochemical changes was observed in dogs given high doses (20.1 IU/kg/day) of pGH. Table I1 has a summary of all drug-related changes. There was a minimal (<lo%) increase in fasted serum glucose levels in some mid-and high-dose pGH-treated dogs and was significant (p 5 0.05) only in study week 3. In study week 11, 2 dogs had high fasted serum glucose values (135 and 151 mg/dl). However, the plasma glycosylated hemoglobin values (week 12) in all dogs were within the normal range (mean values ranged fro-m 2.2% to 2.4%), indicating no evidence of chronic hyperglycemia. Blood urea nitrogen (BUN) levels were slightly decreased (21-39%; p 5 0.05) throughout the study compared to concurrent controls in the high-dose group of dogs and in study weeks 7 and 11 in the mid-dose group. The serum creatinine values in the high-dose group also tended to be slightly lower (p < 0.05) in weeks 3 and 7 of the study. Serum alkaline phosphatase (ALP) activity was slightly higher in high-dose dogs (14-33%) compared to controls. Determination of bone ALP activity showed that there was a significant (p I 0.05) increase throughout the study (15-77%) in high-dose dogs. Although not significant (p > 0.05), the increase in liver ALP activity (17-44%) also contributed to the overall increase in serum ALP activity. Adrenal cortical ALP activity was unchanged (mean values ranged from 1 to 7 UL).
Administration of pGH resulted in dose-related increases in serum calcium and phosphorous levels. The magnitude of increase in serum calcium levels was minimal (mean value 4-10%) and was significant (p 5 0.05) through the mid dose. Similarly, the elevation in serum phosphorous levels (mean values 10-49%) was significant through the mid-dose group. The serum potassium levels increased (p 5 0.05) by 14-18'36 in the high-dose group throughout the study relative to controls. Dose-related increased serum total cholesterol and triglycerides were seen throughout the study. The magnitude of increase (mean values 29-155'36) in serum cholesterol levels was significant (p 5 0.05) through mid dose. Associated with elevated serum cholesterol levels, significant (p 5 0.05) dose-related increased serum triglyceride levels were observed through the mid dose. The magnitude of increases in serum cholesterol and triglyceride levels was minimal and not significant (p I 0.05) at the lowest dose.
Urinnlysis
Administration of high doses (1 IUkglday) of pGH resulted in polyuria in most dogs throughout the study; the observed increased urine volume (-2-fold) was significantly (p I 0.05) greater in weeks 3 and 7 of the study. Associated with increased urine volume, there was a significant decrease (p 5 0.05) in the mean specific gravity of urine when compared with the pretest values (1.034 vs 1.012, 1.020, and 1.020, pretest and weeks 3, 7, and 11, respectively). The other urinary parameters evaluated were within the control ranges.
Senun Honnoiie Levels
Clear dose-related increases in serum GH, IGF-1, and insulin levels were observed in pGH-treated dogs. There was a slight decrease in serum T., levels in high-dose dogs. Serum cortisol and T3 levels were unaffected (data not shown).
G H Levels. As shown in Fig. 2 , GH levels expressed as AUC were significantly (p 5 0.05) increased in both sexes given exogenous GH. The GH AUCs (0-8 hr geometric means) in week 4 were approximately 2-, 8-, and 70-fold greater in the low-, mid-, and high-dose groups, respectively, than in controls.
. GH values in the pretest period were generally consistent (except for one outlier among 224 values) over the 24-hr interval; the absolute values ranged between 0.1 ng/ml to 11.1 ng/ml; the peak values ranged between 2.8 ng/ml to 11.1 ng/ml. In week 4, the 0-hr (predose) values were comparable to pretest values, except in the highdose group, where the peak value was 39.2 ng/ml compared to 7.2 ng/ml in controls. Following dosing in week 4, there was a marked elevation in serum GH levels in pGH-treated groups (up to 479 ng/ml in high dose). In subsequent study weeks (8 and 12), there was a slight increase in GH noted prior to dosing (0 hr) in all pGH groups when compared to vehicle controls. There was no neutralizing antibody to pGH following 14 wk of daily subcutaneous injections with high doses of pGH. Fig. 3 , serum IGF-1 levels expressed as AUC were significantly (~1 5 0 . 0 5 ) increased in pGH-treated dogs. The mean serum IGF-1 AUC(O-Bhr) values in the mid-dose group were 3-5-fold greater than in control and in the high-dose group the values were 6-10-fold higher than controls; in these 2 groups there was a tendency for the AUC values to increase with continued treatment with pGH. The magnitude of increase in serum IGF-1 levels in the low-dose group of dogs was minimal (25-100%) when compared to controls.
ZGF-1 Levels. As shown in
In general, the serum IGF-1 levels showed minimal variation over a 24-hr period in a given dog during the pretest period as well as in study weeks 4, 8, and 12. The pretest IGF-1 peak values ranged from 59 to 265 ng/rnl in females and 104 to 344 ng/ml in males. In contrast, the peak IGF-1 values in dogs treated with high-dose pGH were as high as 1,770 ng/ml and 2,119 ng/ml in females and males, respectively.
Iitsiilirt Levels. As shown in Fig. 4 , there was a dosedependent significant 0, I 0.05) increase in serum insulin levels (expressed as AUC,-,,,) in pGH-treated dogs.
Mean insulin values (AUC,-,,) increased in study weeks 4, 8, and 12 in the mid-and high-dose groups, by about 5-fold and by 10-20-fold, respectively, relative to the control group; most of these increases were due to marked postprandial elevation in serum insulin levels as shown (for males) in Fig. 5 . It should be noted that the high insulin values could not be precisely quantitated. The insulin value used in calculating the AUC was the highest value that could be quantitated. Therefore, the AUC is underestimated in these calculations and is a conservative estimate. The magnitude of insulin elevation in the low-dose group of dogs was within the control range except for female dog values in week 12, which were significantly (p 5 0.05) elevated.
In control dogs, the serum insulin levels were-as high as 50 pIU/ml within ; I few hours (2-4 hr) following feeding (Fig. 5) . In contrast, many high-dose dogs had insulin values that exceeded the limit of quantitation of this assay (>400 pIU/ml). Furthermore, in week 12, mean basal levels (0 and 24 hr) of insulin in the high-dose dogs were high (mean values of 166 and 152 pIU/ml). In the middose group, insulin values increased above control only following feeding (Fig. 5) .
Senan T4 Levels
There was a statistically significant (p 5 0.05) decrease in serum T4 levels in high-dose females in weeks 4, 8, and 12 (data not shown). The magnitude of decrease was slight (30-60%) and the absolute values in the high-dose females ranged from 0.32 to 3.62 pg/dl compared to 1.3 to 4.76 pg/dl in control dogs. In high-dose males, statistically significant (p I 0.05) decrease was evident only in drug week 8; however, all absolute values were within the concurrent control range (0.49-3.37 pg/dl).
Organ Weight Changes
Daily administration of pGH resulted in increased weight of certain organs as shown in Table III trol were made, emphasis was placed on organ weights expressed as a percentage of brain weight rather than on absolute weights to highlight those changes that might be in excess of the general anabolic response. The organs affected included kidneys, liver, thyroid, and adrenal glands. The weight changes in the pituitary and skeletal muscle are the subjects of the accompanying papers (16, 20) .
Kidney weights increased (654%) with increasing doses starting at the lowest dose. Statistical significance (p 5 0.05) was attained at the high dose. Liver weights were increased with increasing doses as well ( 3 4 0 % in females and 15-131% in males); statistical significance was attriined through the high dose in females and through the mid dose in males (p 5 0.05). There was a trend toward increased thyroid weights in females (3-30%) and in males (21-42%); however, none attained statistical significance (p > 0.05). The weights of adrenal glands in the high-dose males only were statistically significantly increased (56%) over those of controls (p 5 0.05).
Gross mid Histoiiiorphologicnl Cliaiiges
Chronic administration of pGH resulted in dose-related gross and/or histomorphological changes in multiple tissues. The incidence of histomorphological changes is summarized in Table IV. The stomach wall was thickened in the high-dose group dogs, which was due to increased thickness of all layers, compared to controls. This was most noticeable grossly in the mucosal layer, especially in the pyloric area. As shown in Fig. 6 , the pyloric mucosa of this high-dose male was diffusely thickened and folded. Histologically, in all highdose dogs, very slight to slight hyperplasia of the mucous neck cells was noted in both the fundic and pyloric mucosa (Fig. 6) . The mucosa was frequently coated with a thick layer of mucus. Three mid-dose and 1 low-dose dog were also affected. In addition to the hyperplastic change, 2 highdose males had pinpoint brown foci in the pyloric mucosa as seen in Fig. 6 . They were shallow focal erosions that seemed to be formed by the sloughing of the proliferative fronds of epithelium sometimes accompanied by a thin neutrophilic infiltrate at the base.
Very slight to moderate centrilobular hepatocellular cytoplasmic rarefaction was seen in 3 males and 3 females in the mid-dose group and in all dogs in the high-dose group. One low-dose male had a very slight degree of this change (Fig. 7 and Table IV ). The rarefaction was characterized by poorly delineated cytoplasmic clear areas. Livers from control and treated dogs stained intensely for glycogen even though all were fasted overnight before necropsy. This was determined by positive periodic acid-Schiff (PAS) staining of the cytoplasm; these rarefied areas of the cytoplasm were almost empty and contained very little PAS-positive material after diastase digestion. By transmission electron microscopy (TEM), the large clear spaces in the cytoplasm seen in the centrilobular hepatocytes, when stained by H&E, were filled with fine grains of glycogen. Organelles were pushed aside by the glycogen, but otherwise, the hepatocytes had a normal appearance by TEM. Cytoplasmic rarefaction of the pancreatic islets was seen in a dose-related pattern. This was characterized by ballooned cells with sparse, dispersed cytoplasm (Table  IV and Fig. 7 ). Less frequently, in the mid-and highdose groups, some islet cells had cytoplasmic droplets, usually 1 per cell, characterized by a dense pink core surrounded by a clear halo. These structures stained intensely with an immumohistochemical stain for insulin. In general, the islets in the pancreases from control dogs stained more homogeneously for insulin than did those from the pGH-treated dogs.
In the marrow of bone sections and in bone marrow smears there was depletion of the erythroid cell series in 7 of 8 high-dose and 2 of 8 mid-and low-dose dogs (Table IV) . In general, although the bone marrow was still quite cellular, there appeared to be a shift toward a more a immature, mainly erythroid. cell type. Very slight to moderate extramedullary hematopoiesis was observed in spleens of mid-and high-dose dogs (Table IV) . In addition to the diffuse changes in the bone marrow, many high-dose dogs with the large costochondral junctions had discrete patches of marrow atrophy adjacent to the expanding cartilage-bone interface.
PRAI 4LADA ET AL TOXICOLOGIC PATHOLOGY Grossly, the costochondral junctions appeared enlarged in some high-dose dogs. Histologically, lateral widening of the cartilage-bone junction of ribs (Fig. 8) and focal osteoblast proliferation of cancellous bone was observed at all doses; the seventy and the incidence of these changes were dose related (Table IV) . Additionally, the ribs in the mid-and high-dose dogs were very slightly thicker than in the controls due to increases in the thickness of cortical bone and fibroblast layer of the periosteum (Fig. 8) .
In the kidneys, glomeruli appeared larger with thicker mesangium, filling Bowman's space (Fig. 9) . The mesangial thickening was due to increased cellularity and collagen (based on evaluation of trichrome-stained sections). In 5 of 8 high-dose dogs, orange-pink glomerular deposits were also seen in H&E-stained sections (Fig. 9) . The deposits were slightly positive with PAS stain, negative for amyloid on Congo red stain, and slightly positive for fibrin based on phosphotungstic acid hematoxylin.
Large skin folds were seen over the forehead and face of pGH-treated dogs at all doses: 3 at the low dose, 7 at the mid dose, and 8 at the high dose. The seventy of this change was also dose related (Table IV) . The folds were due mainly to increased thickness in the dermal collagen layer (Fig. 10 ). There was no subcutaneous edema. In the ovaries, there was an increase in the incidence of stromal hyperplasia (2/4) and stromal vacuolation (4/4) in dogs treated with the high dose of pGH (Fig. 11) .
Although a nondose-related increase (p > 0.05) in ovarian weight was observed in all pGH-treated groups, the histologic changes were limited to ovaries of dogs in the high-dose group. A slight increase in thyroid weight was evident in most pGH-treated dogs (Table 111) ; histologically, only 1 highdose dog had moderate focal follicular cell hyperplasia. There were no histomorphologic changes in adrenal gland to correlate with the observed increased weight in the high-dose group of dogs. DISCUSSION Many of the effects described in pGH-treated dogs are directly or indirectly related to the pharmacological effects of excess circulating GH levels and are consistent with the findings in acromegalic patients (10) . Most of the findings in dogs can be broadly grouped under the anabolic or catabolic effects of GH. GH is believed to exert its anabolic effects indirectly through IGF-1 and the catabolic effects directly through GH (10) . Administration of pGH daily for 12 wk resulted in no antibody formation to GH. This is consistent with the reported finding that pGH and canine GH have identical protein structure Chronic daily subcutaneous administration of pGH to young adult beagle dogs resulted in expected pharmacological effects such as increased body weight gain and increased serum IGF-1 levels. The increased body weight gain in pGH-treated dogs was considered primarily related to increased musculoskeletal growth as evidenced by increase in muscle weight (details in accompanying paper), increased dermal collagen, as well as an increased at SAGE PUBLICATIONS on December 9, 2012 tpx.sagepub.com Downloaded from bone formation. In addition to the gross and histomorphologic changes described, there were increased serum phosphorous and calcium levels as well as increased ALP activity, specifically the bone isozyme, indicating that there was an increased bone turnover in pGH-treated dogs. This is consistent with the earlier studies which showed that administration of bovine GH to dogs results in increased bone formation (11, 12) . Although all dogs received the same amount of food ration in this study, increased weight gain, especially during the first 10 wk of the study, is due to the anabolic effect of pGH. Decreases in serum urea nitrogen and creatinine in pGHtreated dogs further support such a conclusion. Additional body weight gain (between study weeks 10 and 14) following an increase in the food ration was partly related to increased appetite in pGH-treated dogs. Although a total body composition study to determine body fat mass, lean mass, or bone mineral content was not done, the increased weight in pGH-treated dogs was unlikely due to increased body fluid, because there was no clinical or histomorphological evidence of edema. Edema has been reported as one of the side effects of exogenous GH administration in man (21) . The increased weight of several organs in pGH-treated dogs is consistent with the dose-related increased body weight. Thus, most organs were similar to those of controls when the weights were expressed as a percentage of body weight. However, the liver weight was increased as a percentage of body weight in both mid-and high-dose groups; this is believed to be a direct trophic effect of GH on liver parenchyma. Histomorphological examination of the liver suggested increased glycogen accumulation in hepatocytes of pGH-treated dogs. It is likely that altered carbohydrate metabolism as a result of elevated GH levels contributed to the histomorphologic changes in the liver. The changes in thyroid weight of pGH-treated dogs may be related to decreased T4 levels in the highdose group. Although the exact mechanism for the decrease in T4 levels is not clear, it is believed to be due to increased peripheral conversion of T4 to T3 in man (15) . Because hyperthyroidism has been reported (-10%) in acromegalic patients (lo), the increased thyroid weight in pGH-treated dogs is considered related to elevated GH levels. Increased kidney weight in pGH-treated dogs was interpreted to be related to the known trophic effect of elevated IGF-1 levels (9). Increased weight of many organs in pGH-treated dogs is consistent with the published data in rats as well as in dogs with elevated circulating GH levels (9).
Increased serum IGF-1 levels in pGH-treated dogs demonstrated that pGH is biologically active in dogs. Increased serum IGF-1 levels in response to elevated serum GH levels have been reported in dogs (7) . Because serum IGF-1 has a long half-life, there was minimal variation in IGF-1 values of a given dog sample collected over 24 hr. As serum GH is quite variable over a 24-hr period, determination of serum IGF-1 levels from fewer samples will likely provide an accurate assessment of GH status in dogs.
One of the catabolic effects of GH is to antagonize insulin action. In pGH-treated dogs, there was a clear dose-related increase in serum insulin levels, especially soon after feeding (Fig. 5) . Chronic dosing over a 12-wk period resulted in elevated insulin levels in samples taken prior to feeding in dogs given the highest dose of pGH demonstrating that there is increased insulin resistance with time. However, in pGH-treated dogs, there was minimal or no increase in fasted glucose levels even in the highest dose group suggesting that the increase in serum insulin level was able to compensate and maintain normal blood glucose levels despite elevated levels of GH. Furthermore, lack of an alteration in circulating glycosylated hemoglobin levels in pGH-treated dogs supports the conclusion that there was no evidence of a chronic hyperglycemia and the pancreatic islets were able to compensate by increased insulin secretion. The pancreatic islet morphology in pGH-treated dogs is consistent with the changes in serum insulin levels. Despite no clear evidence of hyperglycemia, increased serum insulin levels in pGH-treated dogs suggest that these dogs are in the early stages of developing insulin-resistant diabetes. This is supported by the observed early glomerular changes in kidneys of pGH-treated dogs. Similar glomerular changes have been reported in dogs with elevated GH levels secondary to progesterone treatment (23). Premature glomerular sclerosis has been reported in transgenic mice with high circulating levels of GH (5). In contrast, there is no evidence to suggest that renal function is compromis,ed in acromegalic patients or in patients receiving treatment for chronic renal failure (9). The seventy and the duration of insulin resistance as a result of GH elevation may play an important role in the pathogenesis of glomerulopathy. During the course of the study, thickened and folded skin, especially over the forehead, was the earliest external feature observed in pGH-treated dogs. Histologically, there was increased collagen in dermis with no evidence of subcutaneous edema. This is one of the effects of increased GH levels and is consistent with the findings in earlier studies (8) . The observation in dogs is similar to the findings in acromegalic patients in whom the increased dermal collagen, in addition to the altered musculoskeletal abnormality, contributes to the deformation of facial features (10) .
The cause of the hematological changes observed in pGH-treated dogs was unclear. There was a dose-and 
